Antirheumatic Drug Intake Influence on Occurrence of COVID-19 Infection in Ambulatory Patients with Immune-Mediated Inflammatory Diseases: A Cohort Study.
Antirheumatic drugs
Hydroxychloroquine
Psoriatic arthritis
Rheumatoid arthritis
Sjögren’s syndrome
Systemic lupus erythematosus
Journal
Rheumatology and therapy
ISSN: 2198-6576
Titre abrégé: Rheumatol Ther
Pays: England
ID NLM: 101674543
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
14
07
2020
accepted:
06
09
2021
pubmed:
17
9
2021
medline:
17
9
2021
entrez:
16
9
2021
Statut:
ppublish
Résumé
We aimed to study the prevalence of a history of COVID-19 infection among patients suffering from systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren's syndrome (SjS) or psoriatic arthritis (PsA), and the potential influence of long-term hydroxychloroquine (HCQ) intake. We performed an observational monocentric cohort study at the Adolphe de Rothschild Foundation Hospital ophthalmology division (Paris, France). Electronic medical records (EMR) data were searched for keywords associated with SLE, RA, SjS, or PsA. Patients were contacted by phone and were interviewed using a standardized questionnaire. The primary outcome was the occurrence of a positive COVID-19 test result during the study period. We determined the adjusted association between various antirheumatic drugs intake, COVID-19 risk factors, and occurrence of COVID-19 using a logistic regression model. This study is registered on ClinicalTrials.gov (Identifier: NCT04345159). Patients were recruited between Apr 17, 2020, and Apr 30, 2020 and were recontacted between Oct 6, 2020, and Nov 2, 2020. A total of 569 patients were included, of whom 459 patients were eligible for data analysis. One hundred and eighty-one patients were treated with long-term HCQ and 18 patients had tested positive for COVID-19. No antirheumatic drug intake, including HCQ intake, was significantly associated with an increased or decreased risk of developing COVID-19 infection. No antirheumatic drug intake was associated with an increased or decreased risk of developing COVID-19 infection in our cohort of patients suffering from immune-mediated inflammatory diseases.
Identifiants
pubmed: 34529226
doi: 10.1007/s40744-021-00373-1
pii: 10.1007/s40744-021-00373-1
pmc: PMC8444183
doi:
Banques de données
ClinicalTrials.gov
['NCT04345159']
Types de publication
Journal Article
Langues
eng
Pagination
1887-1895Informations de copyright
© 2021. The Author(s).
Références
Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6(1):16.
doi: 10.1038/s41421-020-0156-0
Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;71(15):732–9.
doi: 10.1093/cid/ciaa237
Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949.
doi: 10.1016/j.ijantimicag.2020.105949
Lagier J-C, Million M, Gautret P, Colson P, Cortaredona S, Giraud-Gatineau A, et al. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: a retrospective analysis. Travel Med Infect Dis. 2020;36:101791.
doi: 10.1016/j.tmaid.2020.101791
Ferreira A, Oliveira-E-Silva A, Bettencourt P. Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection. J Med Virol. 2021;93(2):755–9.
doi: 10.1002/jmv.26286
Seet RCS, Quek AML, Ooi DSQ, Sengupta S, Lakshminarasappa SR, Koo CY, et al. Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: an open-label randomized trial. Int J Infect Dis. 2021;106:314–22.
doi: 10.1016/j.ijid.2021.04.035
Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA. 2020;323(24):2493–502.
doi: 10.1001/jama.2020.8630
Mathian A, Mahevas M, Rohmer J, Roumier M, Cohen-Aubart F, Amador-Borrero B, et al. Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. Ann Rheum Dis. 2020;79(6):837–9.
doi: 10.1136/annrheumdis-2020-217566
Konig MF, Kim AHJ, Scheetz MH, Graef ER, Liew JW, Simard J, et al. Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19. Ann Rheum Dis. 2020;79(10):1386–8.
doi: 10.1136/annrheumdis-2020-217690
Sbidian E, Penso L, Herlemont P, Botton J, Baricault B, Semenzato L, et al. Comment on “Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19” by Konig et al. Long-term exposure to hydroxychloroquine or chloroquine and the risk of hospitalisation with COVID-19: a nationwide, observational cohort study in 54,873 exposed individuals and 155,689 matched unexposed individuals in France. Ann Rheum Dis. 2020. https://doi.org/10.1136/annrheumdis-2020-218647 .
doi: 10.1136/annrheumdis-2020-218647
pubmed: 32859610
Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859–66.
doi: 10.1136/annrheumdis-2020-217871
Rentsch CT, DeVito NJ, MacKenna B, Morton CE, Bhaskaran K, Brown JP, et al. Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform. Lancet Rheumatol. 2021;3(1):e19-27.
doi: 10.1016/S2665-9913(20)30378-7
Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;382(25):2411–8.
doi: 10.1056/NEJMoa2012410
Sammartino D, Jafri F, Cook B, La L, Kim H, Cardasis J, et al. Predictors for inpatient mortality during the first wave of the SARS-CoV-2 pandemic: a retrospective analysis. PLoS ONE. 2021;16(5):e0251262.
doi: 10.1371/journal.pone.0251262
Gerlovin H, Posner DC, Ho Y-L, Rentsch CT, Tate JP, King JT Jr, et al. Pharmacoepidemiology, machine learning and COVID-19: an intent-to-treat analysis of hydroxychloroquine, with or without azithromycin, and COVID-19 outcomes amongst hospitalized US Veterans. Am J Epidemiol. 2021. https://doi.org/10.1093/aje/kwab183 .
doi: 10.1093/aje/kwab183
pubmed: 34165150
Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. N Engl J Med. 2020;383(21):2041–52.
doi: 10.1056/NEJMoa2019014
Schwartz I, Boesen ME, Cerchiaro G, Doram C, Edwards BD, Ganesh A, et al. Assessing the efficacy and safety of hydroxychloroquine as outpatient treatment of COVID-19: a randomized controlled trial. CMAJ Open. 2021;9(2):E693-702.
doi: 10.9778/cmajo.20210069
Sivapalan P, Suppli Ulrik C, Sophie Lapperre T, Dahlin Bojesen R, Eklöf J, Browatzki A, et al. Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19-a randomised double-blinded placebo-controlled trial. Eur Respir J. 2021. https://doi.org/10.1183/13993003.00752-2021 .
doi: 10.1183/13993003.00752-2021
pubmed: 34649975
pmcid: 8186006
Ader F, Peiffer-Smadja N, Poissy J, Bouscambert-Duchamp M, Belhadi D, Diallo A, et al. An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19. Clin Microbiol Infect. 2021. https://doi.org/10.1016/j.cmi.2021.05.020 .
doi: 10.1016/j.cmi.2021.05.020
pubmed: 34048876
pmcid: 8149166
Réa-Neto Á, Bernardelli RS, Câmara BMD, Reese FB, Queiroga MVO, Oliveira MC. An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe COVID-19 patients. Sci Rep. 2021;11(1):9023.
doi: 10.1038/s41598-021-88509-9
Reis G, Moreira Silva EADS, Medeiros Silva DC, Thabane L, Singh G, Park JJH, et al. Effect of early treatment with hydroxychloroquine or lopinavir and ritonavir on risk of hospitalization among patients with COVID-19: the TOGETHER randomized clinical trial. JAMA Netw Open. 2021;4(4):e216468.
doi: 10.1001/jamanetworkopen.2021.6468
Dubée V, Roy P-M, Vielle B, Parot-Schinkel E, Blanchet O, Darsonval A, et al. Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a placebo-controlled double blind trial. Clin Microbiol Infect. 2019. https://doi.org/10.1016/j.cmi.2021.03.005 .
doi: 10.1016/j.cmi.2021.03.005
pubmed: 31306795
Galan LEB, Santos NMD, Asato MS, Araújo JV, de Lima MA, Araújo AMM, et al. Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection. Pathog Glob Health. 2021;115(4):235–42.
doi: 10.1080/20477724.2021.1890887
Johnston C, Brown ER, Stewart J, Karita HCS, Kissinger PJ, Dwyer J, et al. Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: a randomized clinical trial. EClinicalMedicine. 2021;33:100773.
doi: 10.1016/j.eclinm.2021.100773
Hernandez AV, Ingemi J 3rd, Sherman M, Pasupuleti V, Barboza JJ, Piscoya A, et al. Impact of prophylactic hydroxychloroquine on people at high risk of COVID-19: a systematic review and meta-analysis. J Clin Med Res. 2021. https://doi.org/10.3390/jcm10122609 .
doi: 10.3390/jcm10122609
Hernandez AV, Phan MT, Rocco J, Pasupuleti V, Barboza JJ, Piscoya A, et al. Efficacy and safety of hydroxychloroquine for hospitalized COVID-19 patients: a systematic review and meta-analysis. J Clin Med Res. 2021. https://doi.org/10.3390/jcm10112503 .
doi: 10.3390/jcm10112503
Di Castelnuovo A, Costanzo S, Cassone A, Cauda R, De Gaetano G, Iacoviello L. Hydroxychloroquine and mortality in COVID-19 patients: a systematic review and a meta-analysis of observational studies and randomized controlled trials. Pathog Glob Health. 2021;15:1–11.
doi: 10.1080/20477724.2021.1936818
Amani B, Khanijahani A, Amani B. Hydroxychloroquine plus standard of care compared with standard of care alone in COVID-19: a meta-analysis of randomized controlled trials. Sci Rep. 2021;11(1):11974.
doi: 10.1038/s41598-021-91089-3
Axfors C, Schmitt AM, Janiaud P, Van’t Hooft J, Abd-Elsalam S, Abdo EF, et al. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nat Commun. 2021;12(1):2349.
doi: 10.1038/s41467-021-22446-z
Eze P, Mezue KN, Nduka CU, Obianyo I, Egbuche O. Efficacy and safety of chloroquine and hydroxychloroquine for treatment of COVID-19 patients-a systematic review and meta-analysis of randomized controlled trials. Am J Cardiovasc Dis. 2021;11(1):93–107.
pubmed: 33815925
pmcid: 8012280
Yousefghahari B, Navari S, Sadeghi M, Soleimaniamiri S, Soleimaniamiri M, Heidari B, et al. Risk of COVID-19 infection in patients with rheumatic disease taking disease-modifying anti-rheumatic drugs. Clin Rheumatol. 2021. https://doi.org/10.1007/s10067-021-05779-4 .
doi: 10.1007/s10067-021-05779-4
pubmed: 34052904
pmcid: 8164488
Pham K, Torres H, Satlin MJ, Goyal P, Gulick RM. Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases. Rheumatol Adv Pract. 2021;5(1):rkab014.
doi: 10.1093/rap/rkab014
Cordtz R, Lindhardsen J, Soussi BG, Vela J, Uhrenholt L, Westermann R, et al. Incidence and severeness of COVID-19 hospitalisation in patients with inflammatory rheumatic disease: a nationwide cohort study from Denmark. Rheumatology. 2020. https://doi.org/10.1093/rheumatology/keaa897 .
doi: 10.1093/rheumatology/keaa897
Dalton JE, Gunzler DD, Jain V, Perzynski AT, Dawson NV, Einstadter D, Tarabichi Y, Imrey PB, Lewis M, Kattan MW, Yao J, Taksler G, Berg KA, Krieger NI, Kaelber D, Jehi L, Kalra A. Mechanisms of socioeconomic differences in COVID-19 screening and hospitalizations. PLoS ONE. 2021;16(8):e0255343.
doi: 10.1371/journal.pone.0255343
Zerbo O, Lewis N, Fireman B, Goddard K, Skarbinski J, Sejvar JJ, Azziz-Baumgartner E, Klein NP. Population-based assessment of risks for severe COVID-19 disease outcomes. Influenza Other Respir Viruses. 2021.
Sandoval M, Nguyen DT, Vahidy FS, Graviss EA. Risk factors for severity of COVID-19 in hospital patients aged 18–29 years. PLoS ONE. 2021;16(7):e0255544.
doi: 10.1371/journal.pone.0255544
Zhang Y, Khullar D, Wang F, Steel P, Wu Y, Orlander D, Weiner M, Kaushal R. Socioeconomic variation in characteristics, outcomes, and healthcare utilization of COVID-19 patients in New York City. PLoS ONE. 2021;16(7):e0255171.
doi: 10.1371/journal.pone.0255171
Lo CH, Nguyen LH, Drew DA, Warner ET, Joshi AD, Graham MS, Anyane-Yeboa A, Shebl FM, Astley CM, Figueiredo JC, Guo CG, Ma W, Mehta RS, Kwon S, Song M, Davies R, Capdevila J, Sudre CH, Wolf J, Cozier YC, Rosenberg L, Wilkens LR, Haiman CA, Marchand LL, Palmer JR, Spector TD, Ourselin S, Steves CJ, Chan AT, COPE Consortium. Race, ethnicity, community-level socioeconomic factors, and risk of COVID-19 in the United States and the United Kingdom. EClinical Medicine. 2021;38:101029.
doi: 10.1016/j.eclinm.2021.101029